Verdict: Side-by-side breakdown using the Bull Rankings model. REGN scored 68.1, ARGX scored 77.2 — ARGX leads.
Compare another set
Different reporting periods. REGN's fundamentals are as of June 2026, but ARGX's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology · Quality-Growth
68.1
$746.54 · $76.9B
fundamentals as of
Score gap
9.1
ARGX leads
ARGX
argenx SE
Biotechnology · Quality-Growth
77.2
$825.03 · $51.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestREGN18.5x
Fastest growthARGX+89.9%
Strongest balance sheetARGX0.01
Highest qualityARGX72 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
REGN
stronger →← stronger
ARGX
65
Qualityreturns · margins · balance sheet
72
76
Growthrevenue & earnings expansion
98
64
Valuevaluation vs sector peers
65
ARGX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
REGN
ARGX
$3.8bB
FCF
$679mC+
+9.3%B
Rev
+89.9%A
0.09B+
D/E
0.01A
18.5xA-
P/E
31.4xB
1.26B
PEG
1.00B+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
REGN
ARGX
22% above
Price vs fair valuelower is cheaper
229% above
~12%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~47%/yr
-24%
1-yr DCF upside
-77%
-18%
5-yr DCF upside
-70%
-9%
10-yr DCF upside
-55%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
REGN
Why this score
Diluting shareholders
ARGX
The companies
REGNRegeneron Pharmaceuticals, Inc.
Biotechnology · $746.54 · beta 0.15
Why now
Biotechnology · market cap $76.9b. 13% off the 52-week high of $859.34. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $859.04 (implying +15% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $76.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ARGXargenx SE
Biotechnology · $825.03 · beta -0.04
Why now
Biotechnology · market cap $51.9b. Down 23% from 52-week high of $1072.75 — deep drawdown territory. Revenue growing +90% — in hypergrowth territory. 23 sell-side analysts rate this a Buy with a mean 1-yr target of $1,154 (implying +40% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. $51.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 12.5x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where REGN and ARGX diverge
On the headline score the gap is 9.1 points in favor of ARGX. The widest single difference is Growth, where ARGX leads by 21.9 points.
GrowthREGN 76.1 · ARGX 98.0ARGX +21.9
QualityREGN 65.0 · ARGX 72.1ARGX +7.1
ValueREGN 63.9 · ARGX 65.1level
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ARGX or REGN the better stock?
ARGX scores higher: ARGX 77.2, REGN 68.1 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ARGX and REGN differ most?
The widest gap is growth, where ARGX leads by 22 points on the 0–100 pillar scale. ARGX also leads quality, while value is effectively level between them.
How are ARGX and REGN scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.